QT dispersion correlates with systolic rather than diastolic parameters in patients receiving anthracycline treatment

Internal Medicine

Volumn 43, Issue 5, 2004, Pages 379-387

  Nakamae, Hirohisa ^a   Tsumura, Kei ^a   Akahori, Mika ^a   Terada, Yoshiki ^a   Yamane, Takahisa ^a   Hayashi, Takeo ^b   Saito, Ikuko ^b   Kaneko, Mutsuo ^b   Okamoto, Noboru ^c   Ichihara, Yoshio ^d   Ohta, Kensuke ^a   Hino, Masayuki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUKUDA DENSHI CO LTD   (Japan)

^c Aichi Sannomaru Hospital   (Japan)

^d East Medical Center   (Japan)

Author keywords

Anthracycline; Diastolic function; QT dispersion; QTc dispersion; Systolic function

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FDX-6521; IDARUBICIN; MITOXANTRONE; PIRARUBICIN; POWER VISION 6000; QTD1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATION ANALYSIS; DEVICE; DIASTOLIC BLOOD PRESSURE; ECG ABNORMALITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE RELAXATION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; QT DISPERSION; QT INTERVAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; T CELL LEUKEMIA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTHRACYCLINES; AUTOMATION; CASE-CONTROL STUDIES; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HEART FUNCTION TESTS; HEMATOLOGIC NEOPLASMS; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SYSTOLE;

EID: 3042568760     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.379     Document Type: Article

References (33)

1. Bristow MR, Billinghan ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline cardiotoxicity. Cancer Treat Rep 62: 873-879, 1978.
2. Lefrak EA, Pitha J, Rosenhei S, Gottlieb JA. Clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 33: 302-314, 1973.
3. Schwartz RG, McKenzie WB, Alexander S, et al. Congestive heart failure and left ventricular dysfunction compliciting doxorubicin therapy: a 7-year experience using serial radionuclide angiocardiography. Am J Med 82: 1109-1118, 1987.
4. Dritsas A, Sbarouni E, Gilligan D, Nihoyannopoulos P, Oakley CM. QT-interval abnormalities in hypertrophic cardiomyopathy. Clin Cardiol 15: 739-742, 1992.
5. Grimm W, Steder U, Menz V, Hoffmann J, Grote F, Maisch B. Clinical significance of increased QT dispersion in the 12-lead standard ECG for arrhythmia risk prediction in dilated cardiomyopathy. Pacing Clin Electrophysiol 19: 1886-1889, 1996.
6. Spargias KS, Lindsay SJ, Kawar GI, et al. QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure. Eur Heart J 20: 1158-1165, 1999.
7. Zabel M, Klingenheben T, Franz MR, Hohnloser SH. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: Results of a prospective, long-term follow-up study. Circulation 97: 2543-2550, 1998.
8. Glancy JM, Garratt CJ, Woods KL, de Bono Dp. QT dispersion and mortality after myocardial infarction. Lancet 345: 945-948, 1995.
9. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 63: 827-834, 1979.
10. Postma A, Bink-Boelkens MT, Beaufort-Krol GC, et al. Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol 26; 230-237, 1996.
11. Nousiainen T, Vanninen E, Rantala A, Jantunen E, Hartikainen J. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J Intern Med 245: 359-364, 1999.
12. Orditura M, Sarubbi B, DeVita F, et al. Prolonged corrected QT dispersion: Early sign of doxorubicin cardiotoxicity? Oncology reports 4: 1047-1050, 1997.
13. Sarubbi B, Orditura M, Ducceschi V, et al. Ventricular repolarization time indexes following anthracycline treatment. Heart Vessels 12: 262-266, 1997.
14. Herait P, Poutignat M, Marty M, Bugat R. Early assessment of a new anticancer drug analogue: are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer 28: 1670-1676, 1992.
15. Nakamae H, Tsumura K, Hino M, Hayashi T, Tatsumi N. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet 355: 805-806, 2000.
16. Casazza AM, Bertazzoli C, Pratesi G, Bellini O, Marco A. Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin (4-DMD) in mice. P AM Assoc Canc Res 20: 16, 1979.
17. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98: 1928-1936, 1998.
18. Brendorp B, Elming H, Jun L, et al. QT dispersion has no prognostic information for patients with advanced congestive heart failure and reduced left ventricular systolic function. Circulation 103: 831-835, 2001.
19. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 7: 353-370, 1920.
20. Moller JE, Husic M, Sondergaard E, Poulsen SH, Egstrup K. Relation of early changes of QT dispersion to changes in left ventricular systolic and diastolic function after a first acute myocardial infarction. Scand Cardiovasc J 36: 225-230, 2002.
21. Oh JK, Appleton CP, Hatle LK, Nishimura RA, Seward JB, Tajik AJ. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 10: 246-270, 1997.
22. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2: 358-367, 1989.
23. Himelman RB, Cassidy MM, Landzberg JS, Schiller NB. Reproducibility of quantitative two-dimensional echocardiography. Am Heart J 115: 425-431, 1988.
24. Harada K, Suzuki T, Tamura M, Ito T, Shimada K, Takada G. Effect of aging from infancy to childhood on flow velocity patterns of pulmonary vein by Doppler echocardiography. Am J Cardiol 77: 221-224, 1996.
25. Szymanski P, Swiatkowski M, Rezler J, Budaj A. The relationship between diastolic function of the left ventricle and QT dispersion in patients with myocardial infarction. Int J Cardiol 69: 245-249, 1999.
26. Cowan JC, Yusoff K, Moore M, et al. Importance of lead selection in QT interval measurement. Am J Cardiol 61: 83-87, 1988.
27. Henein M. The relationship between diastolic function of the left ventricle and QT dispersion in patients with myocardial infarction. Int J Cardiol 71: 195, 1999.
28. Gemici K, Baran I, Gullulu S, Kazazoglu AR, Cordan J, Ozer Z. Evaluation of diastolic dysfunction and repolarization dispersion in Behçet's disease. Int J Cardiol 73: 143-148, 2000.
29. Kors JA, van Herpen G, van Bemmel JH. QT dispersion as an attribute of T-loop morphology. Circulation 99: 1458-1463, 1999.
30. Malik M, Acar B, Gang Y, Yap YG, Hnatkova K, Camm AJ. QT dispersion does not represent electrocardiographic interlead heterogeneity of ventricular repolarization. J Cardiovasc Electrophysiol 11: 835-843, 2000.
31. Di Bernardo D, Langley P, Murray A. Dispersion of QT intervals: a measure of dispersion of repolarization or simply a projection effect? Pacing Clin Electrophysiol 23: 1392-1396, 2000.
32. Suzuki J, Yanagisawa A, Shigeyama T, et al. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Angiology 50: 37-45, 1999.
33. Sung RYT, Huang GY, Shing MK, et al. Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int J Cardiol 60: 239-248, 1997.